World J Hepatol. 2015 Nov 08;7(25):2610-8. doi: 10.4254/wjh.v7.i25.2610.

Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease.

World journal of hepatology

Bharat K Puchakayala, Siddharth Verma, Pushpjeet Kanwar, John Hart, Raghavendra R Sanivarapu, Smruti R Mohanty

PMID: 26557954 PMCID: PMC4635147 DOI: 10.4254/wjh.v7.i25.2610

Abstract

AIM: To study clinical and histopathological features of nonalcoholic fatty liver disease (NAFLD) in patients with and without type 2 diabetes mellitus (T2DM) using updated nonalcoholic steatohepatitis clinical research network (NASH-CRN) grading system.

METHODS: We retrospectively analyzed data of 235 patients with biopsy proven NAFLD with and without T2DM. This database was utilized in the previously published study comparing ethnicity outcomes in NAFLD by the same corresponding author. The pathology database from University of Chicago was utilized for enrolling consecutive patients who met the criteria for NAFLD and their detailed clinical and histopathology findings were obtained for comparison. The relevant clinical profile of patients was collected from the Electronic Medical Records around the time of liver biopsy and the histology was read by a single well-trained histopathologist. The updated criteria for type 2 diabetes have been utilized for analysis. Background data of patients with NASH and NAFLD has been included. The mean differences were compared using χ(2) and t-test along with regression analysis to evaluate the predictors of NASH and advanced fibrosis.

RESULTS: Patients with NAFLD and T2DM were significantly older (49.9 vs 43.0, P < 0.01), predominantly female (71.4 vs 56.3, P < 0.02), had higher rate of metabolic syndrome (88.7 vs 36.4, P < 0.01), had significantly higher aspartate transaminase (AST)/alanine transaminase (ALT) ratio (0.94 vs 0.78, P < 0.01) and Fib-4 index (1.65 vs 1.06, P < 0.01) as markers of NASH, showed higher mean NAFLD activity score (3.5 vs 3.0, P = 0.03) and higher mean fibrosis score (1.2 vs 0.52, P < 0.01) compared to patients with NAFLD without T2DM. Furthermore, advanced fibrosis (32.5 vs 12.0, P < 0.01) and ballooning (27.3 vs 13.3, P < 0.01) was significantly higher among patients with NAFLD and T2DM compared to patients with NAFLD without T2DM. On multivariate analysis, T2DM was independently associated with NASH (OR = 3.27, 95%CI: 1.43-7.50, P < 0.01) and advanced fibrosis (OR = 3.45, 95%CI: 1.53-7.77, P < 0.01) in all patients with NAFLD. There was a higher rate of T2DM (38.1 vs 19.4, P < 0.01) and cirrhosis (8.3 vs 0.0, P = 0.01) along with significantly higher mean Bilirubin (0.71 vs 0.56, P = 0.01) and AST (54.2 vs 38.3, P < 0.01) and ALT (78.7 vs 57.0, P = 0.01) level among patients with NASH when compared to patients with steatosis alone. The mean platelet count (247 vs 283, P < 0.01) and high-density lipoprotein cholesterol level (42.7 vs 48.1, P = 0.01) was lower among patients with NASH compared to patients with steatosis.

CONCLUSION: Patients with NAFLD and T2DM tend to have more advanced stages of NAFLD, particularly advanced fibrosis and higher rate of ballooning than patients with NAFLD without T2DM.

Keywords: Advanced fibrosis; Liver biopsy; Non-alcoholic fatty liver disease; Non-alcoholic fatty liver disease activity score; Non-alcoholic steatohepatitis; Type 2 diabetes

References

1. Semin Liver Dis. 2004 Nov;24(4):349-62 - PubMed
2. Am J Gastroenterol. 1999 Sep;94(9):2467-74 - PubMed
3. Diabetes Care. 2014 Jan;37 Suppl 1:S81-90 - PubMed
4. Hepatology. 2003 Apr;37(4):917-23 - PubMed
5. J Hepatol. 2009 Apr;50(4):797-804 - PubMed
6. Liver Int. 2011 May;31(5):700-6 - PubMed
7. Hepatology. 2011 Aug;54(2):463-71 - PubMed
8. J Gastroenterol Hepatol. 2004 Aug;19(8):854-8 - PubMed
9. Hepatology. 2012 Sep;56(3):943-51 - PubMed
10. J Gastroenterol. 2013 Apr;48(4):515-25 - PubMed
11. Ann Med. 2011 Dec;43(8):617-49 - PubMed
12. Hepatology. 1999 Dec;30(6):1356-62 - PubMed
13. J Assoc Physicians India. 2009 Mar;57:205-10 - PubMed
14. Clin Gastroenterol Hepatol. 2004 Mar;2(3):262-5 - PubMed
15. Hepatology. 2011 Mar;53(3):810-20 - PubMed
16. Hepatology. 2007 Apr;45(4):846-54 - PubMed
17. J Hepatol. 2005 Jan;42(1):132-8 - PubMed
18. Hepatology. 2005 Jun;41(6):1313-21 - PubMed
19. JAMA. 2001 May 16;285(19):2486-97 - PubMed
20. Hepatology. 2006 Oct;44(4):865-73 - PubMed
21. Ann Hepatol. 2006 Jan-Mar;5(1):30-3 - PubMed
22. Hepatology. 2010 Feb;51(2):454-62 - PubMed
23. J Dig Dis. 2008 May;9(2):63-7 - PubMed
24. JAMA. 2011 Apr 27;305(16):1659-68 - PubMed
25. Dig Dis Sci. 2008 Mar;53(3):785-8 - PubMed
26. Hepatology. 2010 Mar;51(3):828-35 - PubMed
27. Liver Int. 2008 Apr;28(4):519-24 - PubMed
28. Gut. 2013 Apr;62(4):606-15 - PubMed

Publication Types

• Journal Article